![](/img/cover-not-exists.png)
C43Everolimus-exemestane (EE) vs palbociclib-letrozole (PL) or palbociclib-fulvestrant (PF) in the treatment of metastatic HR+, HER2- breast cancer. Indirect comparisons with network meta-analysis for daily clinical practice
Stocchi, L, Gianni, L, Nicolini, M, Santelmo, C, Carminati, O, Arcangeli, V, Papi, M, Cherubini, C, Polselli, A, Tassinari, DVolume:
28
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx424.042
Date:
October, 2017
File:
PDF, 81 KB
2017